Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Withdrawn 1Recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

NET 1Gastrointestinal 1Endocrine 1

Conditions

Pheochromocytoma 4Paraganglioma 4Neuroendocrine Tumors 4Meningioma 2Gastro-enteropancreatic neuroendocrine tumor 2von Hippel-Lindau Disease 1Thyroid cancer, Hurthle cell 1Thyroid Neoplasms 1Thyroid Cancer, Papillary 1Prostatic Neoplasms 1Pancreatic Neoplasms 1Neuroectodermal Tumors, Primitive 1Neuroblastoma 1Neoplasms 1Multiple Endocrine Neoplasia Type 1 1Kidney Neoplasms 1Hypertension 1Head and Neck Neoplasms 1Carcinoma, Medullary 1Adenocarcinoma, Follicular 1

Interventions

Temozolomide 3Cyclophosphamide 3Etoposide 2ibrutinib 1gallium Ga 68 dotatate 1fludarabine 1etoposide phosphate 1belzutifan 1Zoledronic Acid 1Vincristine 1Thiotepa 1Tamoxifen 1Standard of Care 1Radiotherapy 1ONC206 1Nivolumab 1Mesna 1Isotretinoin 1Hydrocortisone 1Granulocyte Colony-Stimulating Factor 1Filgrastim 1Eflornithine 1Drug Therapy 1Cisplatin 1Celecoxib 1Carboplatin 1Blood Specimen Collection 1Automobiles 11-methyltryptophan 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Recruiting × Neuroectodermal Tumors, Primitive × gallium Ga 68 dotatate × Clear all
NCT04074135 2026-04-20

Natural History and Management of Von Hippel-Lindau (VHL) Associated Pancreatic Neuroendocrine Tumors

National Institutes of Health Clinical Center (CC)

Phase 2 Recruiting
740 enrolled
EndocrineGastrointestinalNET

von Hippel-Lindau Disease, Pancreatic Neoplasms, Neuroectodermal Tumors, Primitive, Neuroendocrine Tumors, Multiple Endocrine Neoplasia Type 1

Data powered by HemOnc (CC BY 4.0) Colophon âš¡